# Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers

> **NCT02478463** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 19 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus
- HIV Infections

## Interventions

- **DRUG:** Cabotegravir tablet 30 mg once daily for 28 days.
- **DRUG:** Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.

## Key facts

- **NCT ID:** NCT02478463
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-27
- **Primary completion:** 2019-07-25
- **Final completion:** 2019-07-25
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2020-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02478463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02478463, "Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02478463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*